Disease in a Dish: Creating Human Tissues In Vitro

ASDs

The Evolving Science of Amorphous Solid Dispersions

Pharma's Almanac

OpenAI Funding

OpenAI Foundation: The Why and How of Its Life Science Research Funding Agenda

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Liver Cancer

Overcoming Resistance in the New Era of Liver Cancer Immunotherapy

David Alvaro, Ph.D.

Pharma's Almanac

CLD

Can Mammalian Cell-Line Engineering Become a High-Throughput Design Problem?

Pharma's Almanac

Formulation Models

Predictive Formulation: Can Modeling Reduce Empirical Development?

David Alvaro, Ph.D.

Pharma's Almanac

Viral Vectors

Gene Therapy Manufacturing After the Capacity Boom

David Alvaro, Ph.D.

Pharma's Almanac

New Technology

What are the key bottlenecks preventing rapid adoption of novel technologies?

Pharma's Almanac

Heme-Onc

Therapeutic and Diagnostic Advances Benefiting Patients with Hematologic Malignancies

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Heme-Onc

The Next Generation of Targeted Therapies in Hematologic Malignancies

DDC Development

Building Better Combination Products by Engaging Device Development Earlier

Loganathan S.

OneSource Specialty Pharma

Allogeneic CAR-T

Can Allogeneic Cell Therapy Solve the CAR-T Access Problem?

Pharma's Almanac